Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Latest News about Todos Medical
Recent news which mentions Todos Medical
Meet The Company Developing Advanved Blood Tests To Detect Cancer And Other Diseases
August 11, 2022
Tickers
TOMDF
Tags
Exclusives
Market News
Benzinga
From
Benzinga
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength including 5 Day Dosing, 30 Day Dosing And 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
May 02, 2022
Tickers
TOMDF
Tags
Market News
Penny Stocks
Benzinga
From
Benzinga
Todos Medical Initiates IRB-Waived Tollovid® Market Research Study And Announces 50% Price Reduction Until May 30th, 2022
April 27, 2022
Tickers
TOMDF
Tags
Penny Stocks
Benzinga
Market News
From
Benzinga
Todos Medical To Present At The Emerging Growth Conference
April 25, 2022
Tickers
TOMDF
Tags
Benzinga
Penny Stocks
Market News
From
Benzinga
Todos Medical Appoints Philippe Goix As Chief Commercial Officer For Provista Diagnostics
April 21, 2022
Tickers
TOMDF
Tags
Penny Stocks
Benzinga
Market News
From
Benzinga
Todos Medical Reports 2nd Long COVID Case Study And Launches Website For Physicians And Pediatricians To Indicate Interest In Participating In Tollovid® Long COVID Clinical Study
April 20, 2022
Tickers
TOMDF
Tags
TOMDF
General
Todos Medical
From
Benzinga
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid® by LGC Group
April 20, 2022
Tickers
TOMDF
Tags
Market News
Benzinga
Penny Stocks
From
Benzinga
New Study Reportedly Calls Into Question Merck's Ivermectin COVID Off Label Use And May Bolster 3CL Protease Inhibitors Such As Tollovid
April 12, 2022
Tickers
MRK
PFE
TOMDF
Tags
Market News
MRK
Benzinga
From
Benzinga
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate Of Free Sale With Daily And Acute Dosing On The Label
April 06, 2022
Tickers
TOMDF
Tags
Todos Medical
General
TOMDF
From
Benzinga
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants
April 04, 2022
Tickers
TOMDF
Tags
Todos Medical
TOMDF
General
From
Benzinga
UPDATE: Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
April 04, 2022
Tickers
TOMDF
Tags
Penny Stocks
Benzinga
Market News
From
Benzinga
Todos Medical Reports Fourth-Quarter And Full-Year 2021 Financial Results And Corporate Updates
April 01, 2022
Tickers
TOMDF
Tags
Market News
Penny Stocks
Benzinga
From
Benzinga
Todos Medical Reports Case Study Of Patient With Long COVID
March 31, 2022
Tickers
TOMDF
Tags
Penny Stocks
Benzinga
Market News
From
Benzinga
Billy Blanks® Endorses Todos Medical's Line Of Tollovid® Products
March 28, 2022
Tickers
TOMDF
Tags
Benzinga
Penny Stocks
Market News
From
Benzinga
Todos Medical To Present At The Proactive One2One Virtual Forum
March 17, 2022
Tickers
TOMDF
Tags
TOMDF
General
Todos Medical
From
Benzinga
Todos Medical Acquires Lucrative NLC Assets For Pennies On The Dollar
March 16, 2022
Tickers
GILD
MRK
PFE
TOM
Tags
Benzinga
PFE
Market News
From
Benzinga
Todos Medical Completes Acquisition Of Key Assets And Intellectual Property From NLC Pharma
March 16, 2022
Tickers
TOMDF
Tags
Penny Stocks
Benzinga
Market News
From
Benzinga
Todos Medical To Present At The Emerging Growth Conference
March 15, 2022
Tickers
TOMDF
Tags
TOMDF
General
Todos Medical
From
Benzinga
Todos Medical Appoints Greg Meiselbach As Vice President Of Government Affairs
March 08, 2022
Tickers
TOMDF
Tags
Market News
Penny Stocks
Benzinga
From
Benzinga
Abbott Labs Outlook Cools the Omicron Led Testing Boom
January 28, 2022
Tickers
ABT
CODX
LH
MRK
Tags
QDEL
MRK
Market News
From
Benzinga
Todos Medical And NLC Pharma Announce Primary And Secondary Endpoints Met In NLC-V-01 Phase 2 Clinical Trial Of Oral Antiviral 3CL Protease Inhibitor Tollovir™ In The Treatment Of Hospitalized COVID-1
January 27, 2022
Tickers
TOMDF
Tags
Press Releases
Biotech
Partner Content
From
Benzinga
Todos Medical Announces Data Lock in Tollovir™ Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients
January 24, 2022
Tickers
TOMDF
Tags
Todos Medical
General
TOMDF
From
Benzinga
PEPPERDINE UNIVERSITY HOSTS THE 22ND ANNUAL CELEBRITY FLAG FOOTBALL CHALLENGE®, PRESENTED BY TODOS MEDICAL'S TOLLOVID®
January 19, 2022
Tickers
TOMDF
Tags
Market News
Benzinga
Penny Stocks
From
Benzinga
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
January 18, 2022
Tickers
MRK
PFE
TOMDF
Tags
Todos Medical
General
TOMDF
From
Benzinga
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022
January 12, 2022
Tickers
TOMDF
Tags
Todos Medical
General
TOMDF
From
Benzinga
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir™ on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022
January 11, 2022
Tickers
TOMDF
Tags
Press Releases
Biotech
Partner Content
From
Benzinga
Todos Medical to Present at January 5, 2022 Emerging Growth Conference
January 03, 2022
Tickers
TOMDF
Tags
Press Releases
Biotech
Partner Content
From
Benzinga
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
December 29, 2021
Tickers
CYDY
GILD
GSK
LLY
Tags
VIR
Opinion
CYDY
From
Benzinga
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer's Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing
December 23, 2021
Tickers
PFE
TOMDF
Tags
PFE
Benzinga
Penny Stocks
From
Benzinga
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States
December 22, 2021
Tickers
TOMDF
Tags
Partner Content
Press Releases
Biotech
From
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.